Clinical Trial Update: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Cavosonstat Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD) [Phase 2]

View source ↗

Summary

A Phase 2 randomized, double-blind trial evaluating cavosonstat versus placebo for 24 weeks in adults with chronic obstructive pulmonary disease (COPD).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Cavosonstat (Cavosonstat)

Snippet

Sponsor: GSNOR Therapeutics, Inc. | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Status: UNKNOWN